Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Autor: Jansen, Y.J.L. ^*, Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Publikováno v: In Annals of Oncology July 2019 30(7):1154-1161

109P Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy

Autor: Noringriis, I.M., Donia, M., Bastholt, L., Schmidt, H., Haslund, C.A., Ellebæk, E., Svane, I-M.

Publikováno v: In Immuno-Oncology and Technology December 2023 20 Supplement

Does sex affect the efficacy of immune checkpoint inhibitors? A national Danish melanoma study

Autor: Petersen, S. K., Schmidt, H., Ellebæk, E., Haslund, C. A., Hansen, C. R., Bastholt, L.

Publikováno v: Petersen, S K, Schmidt, H, Ellebæk, E, Haslund, C A, Hansen, C R & Bastholt, L 2022, ' Does sex affect the efficacy of immune checkpoint inhibitors? A national Danish melanoma study ', Annals of Oncology, vol. 33, no. Suppl. 7, 852P, pp. S940 . https://doi.org/10.1016/j.annonc.2022.07.978

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::89faa82dabf361ee3afce675924d55e8
https://vbn.aau.dk/da/publications/60aa0253-41d0-47cc-8a18-f6e1bd36a74c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Autor: Brandberg, Y., Aamdal, S., Bastholt, L., Hernberg, M., Stierner, U., von der Maase, H., Hansson, J.

Publikováno v: In European Journal of Cancer September 2012 48(13):2012-2019